News

Previous news stories

  • 11.2015 Alvéole will attend the ASCB meeting in San Diego from 12 to 16 December 2015 to present Primo, its protein printing technology
  • 05.2015 Alvéole will attend the Imaging The Cell conference in Bordeaux from 24 to 26 June 2015 to present Primo, its protein printing technology
  • 02.2015 Alvéole signs with the MBI from the University of Singapore a research contract and a license option for the development of a new cellular microenvironment control device
  • 07.2014 Alvéole won the Worldwide Innovation Challenge 2030 for the Personalised Medicine area
  • 07.2014 Alvéole won the Worldwide Innovation Challenge 2030 for the Personalised Medicine area
  • 05.2014 Thamis delivers the last series of hodoscopes to MedAustron and concludes a 36-unit program dedicated to beam diagnostic in hadrontherapy
  • 01.2014 In collaboration with Professor Christian Roux and the Bone Diseases Evaluation Center of the Cochin Hospital, Azalée starts a clinical pilot trial for bone fragility assessment
  • 01.2014 Alvéole signs a 2-patent exclusive license agreement with the CNRS to operate the technology "microsticker"
  • 11.2013 Supported by three research teams from the Ecole Normale Supérieure and the Institut Curie that use Alvéole devices, the Biomicrograd research program gets financial support from the Pierre-Gilles de Gennes Foundation
  • 07.2013 Easy Life Science has been exhibitor at BIOTECHNICA 2013, 08-10 October in Hannover
  • 02.2013Quattrocento moves into its new premises in the incubator Paris Santé Cochin
  • 11.2012 Azalée signs a research contract with the Laboratoire d’Imagerie Paramétrique
  • 11.2012 Creation of Azalée, a subsidiary of Quattrocento, specialized in ultrasound devices for bone assessment
  • 06.2012The first series of hodoscopes delivered by Thamis to MedAustron is accepted
  • 06.2012Quattrocento attends CNRS training sessions for valorization organized in Caen
  • 03.2012The first Thamis hodoscope leaves the manufacturing plant
  • 02.2012 Elice recruits Fabrice RICHARD as Chief Operating Officer in charge of industrial and sales development
  • 12.2011 Quattrocento increases its capital to raise it to 1.3 million euros
  • 10.2011Recruits David POIZAT as Technical and Quality Manager
  • 10.2011Thamis signs a patent and know-how license agreement with the CNRS to operate the hodoscopes developed at the Laboratoire Le Prince Ringuet CNRS/IN2P3
  • 09.2011 Alvéole joins the Paris Biotech Santé incubator
  • 09.2011 Creation of Thamis, a subsidiary of QUATTROCENTO, specialized in control solutions and dosimetry for hadrontherapy
  • 08.2011 Quattrocento signs a contract with MedAustron, the future hadrontherapy center in Austria, for the production of hodoscopes dedicated to particle beam control
  • 12.2010 Alvéole signs a research contract with the Pierre-Gilles de Gennes foundation and the Ecole Normale Supérieure
  • 12.2010 Creation of Alvéole, a company specialized in cell assays
  • 06.2010 Quattrocento establishes its offices in the heart of the Latin Quarter, on the premises of the Ecole Supérieure de Physique et Chimie Industrielle (ESPCI)
  • 06.2010 The company Easy Life Science (Elice) wins the 2010 national competition for assistance in the creation of innovative technology companies, "development" category
  • 04.2010 Quattrocento is created in Paris, an SAS [Simplified Business Corporation] with capital of 54,125 euros
© Quattrocento 2012